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Abstract 
Background: Pompe disease (PD) is a rare inherited disorder caused by the deficiency of acid‑α glucosidase, which 
leads to the impairment of organ and tissue functions and causes disabilities. As the first national survey on patients 
with late‑onset PD (LOPD) in China, this study investigated the quality of life (QOL) of adult patients with LOPD in 
China and explored its contributors.
Methods: Data were derived from a nation‑based, cross‑sectional, self‑response survey on rare diseases (RDs) in early 
2018. Answers from 68 adult Chinese patients with LOPD were used for data analysis. QOL was measured using the 
World Health Organization Quality of Life: Brief Version. Covariates included age, gender, education, employment, reli‑
ance on assistive devices, medication history, social support, and disease economic burden. Data were analyzed using 
linear regression in R.
Results: For adult patients with LOPD, the average scores and standard deviations (SD) of the four dimensions of QOL 
were physical health = 33.77 (SD = 18.28), psychological health = 43.81 (SD = 21.70), environmental health = 39.43 
(SD = 16.93), and social relationship = 46.20 (SD = 19.76); the scoring for each dimension was evaluated on a scale of 
0 to 100. At the significance level of p < 0.05, with increasing age, the patients experienced a significant decrease in 
physical health QOL (β = − 0.75) and environmental health QOL (β = − 0.79). Those who relied heavily on assistive 
devices had lower perceived physical health (β = − 17.8), psychological health (β = − 22.76), environmental health 
(β = − 17.8), and social relationships (β = − 22.12) than those who did not. A one‑unit increase in the amount of social 
support, as a form of social interaction, led to a significant increase in physical health (β = 0.28), psychological health 
(β = 0.71), environmental health (β = 0.72), and social relationships (β = 0.70).
Conclusion: Adult Chinese patients with LOPD had a lower physical health and QOL compared to their counter‑
parts with other RDs. Being employed was found to affect the QOL of adult Chinese patients with LOPD in almost 
all dimensions. Encouraging adult Chinese patients with LOPD to be socially active and help them become more 
involved in social life might improve their QOL.
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Background
Pompe disease (PD), also known as glycogen storage dis-
ease type II, is an inherited disorder caused by the defi-
ciency of acid-α glucosidase (GAA) [1]. PD is generally 
classified into two forms: (1) infantile-onset PD (IOPD) 
when the disease is characterized by cardiomyopathy, 
respiratory insufficiency, and severe muscle hypotonia, 
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and presents during the first year of life, and (2) late-
onset PD (LOPD), which encompasses the remaining 
patients with PD who can present at less than 12 months 
without cardiomyopathy or present after 12 months [2]. 
In patients with PD, the accumulation of glycogen in the 
skeletal muscles, heart, liver, and nervous system causes 
a decline in their quality of life (QOL) and finally leads to 
disabilities or even death [3, 4].
The prevalence of PD is related to ethnicity or the geo-
graphic area studied [5]. According to a recent study in 
Taiwan, the birth prevalence of IOPD in Taiwan is 1 in 
52,000, and of LOPD is about 1 in 25,000 [6]. Since main-
land China does not have its own official estimates, using 
the Taiwanese birth prevalence as a proxy, and the num-
ber of new births in China in 2018 (15,230,000), the num-
ber of individuals born with IOPD in China in 2018 can 
be estimated to be at 293 (52,000/15,230,000), and indi-
viduals with LOPD at 609 (25,000/15,230,000). Although 
having a relatively small population size, PD is one of the 
5% of all rare diseases (RDs) that have certain treatments, 
most of which are labeled orphan drugs that often imply 
a small consumer market, a high price, and a heavy finan-
cial burden for their patients. As a result, the quality of 
life in patients with PD and those associated with them is 
of great concern.
International studies found that LOPD is negatively 
associated to QOL in physical health domains, while 
inconsistent evidence was found for QOL in mental 
health and functional-emotional domains [7–9]. Despite 
the negative consequences of PD on physical health, 
ongoing and chronic illness stressors may induce emo-
tional and cognitive adjustments to the disease. Some 
patients may handle the psychological burden of PD 
relatively well, while others may not [10]. Variations in 
the QOL of patients with LOPD were observed across 
countries and ethnicities. For instance, the International 
Pompe Survey found that among 210 patients with LOPD 
in five countries, patients in the United Kingdom had sig-
nificantly lower scores in vitality but much higher scores 
in perceived general health than American, Australian, 
German, and Dutch patients [8]; and in other dimen-
sions, i.e., social and emotional functioning, Austral-
ians performed the worst among the five focal countries. 
Despite the emphasis on international and inter-racial 
variations, previous studies were mainly conducted in 
Europe and North America, while the situation in China 
has never been comprehensively reported.
Among the very few studies on the determinants of 
QOL in patients with PD, those in Western societies have 
emphasized enzyme replacement therapy (ERT) as a sig-
nificant promoter of QOL, especially at the early stages 
of treatment. However, adverse infusion reactions have 
also been reported [11]. In China, it is estimated that 
the average annual cost of ERT for an adult PD patient 
is around RMB 3,000,000 (1 USD ~ 7 RMB), which is 
over four times the average annual household income 
for a Chinese family. Considering the low coverage rate 
of social and commercial insurance for ERT, Chinese 
patients with PD are fully exposed to the potentially cata-
strophic consequences of the disease. By the end of 2017, 
among the 61 patients with PD (including both IOPD 
and LOPD) who were registered to a national PD patient 
organization, only 12 had ever used the only avail-
able ERT in China, alglucosidase alfa. Among these 12, 
only four patients had used the medicine continuously, 
and none had used it up to the dosage approved by the 
National Medical Products Administration (i.e., 20  mg/
kg every other week [12]. From 2014 to 2018, 14 child 
patients with PD passed away, and 11 of them had never 
used the drug due to unaffordability [12]. Considering 
the high cost and low coverage of ERT, the levels and 
determinants of QOL are of great concern in Chinese 
adult patients with LOPD. Therefore, the main objec-
tive of this study was two-fold: (1) to assess the QOL of 
adult patients with LOPD in China, and (2) to explore the 
social and economic factors that may contribute to it.
Methods
Sampling methods
The data used for this research were derived from a 
large, nation-based, cross-sectional survey among people 
affected by RDs in China in 2018 [13–15]. Since no com-
plete sample frame of patients with RDs exists due to the 
fact that the epidemiological information of these people 
is largely unknown in China, a non-probability conveni-
ence sampling method was used to recruit participants in 
collaboration with a variety of national RD patient organ-
izations, namely the Illness Challenge Foundation and its 
“29 + Alliance” for RD patient organizations, including 
the China Pompe Care Center (CPCC), the only national 
Pompe patient organization in China. The survey details 
were distributed via online and offline social networks. 
Individual patients also shared recruitment information.
Procedure
The survey was conducted primarily online (www. wenju 
an. com) to maximize accessibility to the dispersed pop-
ulation. It was approved by the Committee on the Use 
of Human and Animal Subjects in the Teaching and 
Research of Hong Kong Baptist University (No: FRG2/15-
16/052). Although the survey was self-administered, pre-
vious studies have shown that this type of survey could 
yield a higher response rate than the physical mail survey 
and more accurate results than the telephone survey [16, 
17]. Participants followed a link to the survey website. 
Informed consent was obtained from the participants 
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before they were presented the questionnaire. At the 
beginning of the questionnaire, a series of questions were 
used to identify the target respondents of the survey (i.e., 
people affected by RDs in China). Patients under 18 were 
asked to end the survey and refer the survey link to their 
legal guardians. Main caregivers and patients were iden-
tified and assigned to one of the two versions of the ques-
tionnaire. The two versions covered the same measures, 
but the questions were formed differently to retrieve 
more accurate answers. The survey was conducted from 
January 1 to February 15, 2018.
Patients with PD in this study
In total, 2007 valid responses were collected from the 
2018 survey, which covered 94 distinctive types of RDs. 
The survey included responses from 92 patients with PD. 
Although small in number, the 14 patients with IOPD 
and 78 patients with LOPD were all patients with PD with 
a definitive clinical diagnosis and had registered with the 
CPCC by the time of the survey. In other words, these 92 
patients comprised the entire population of patients with 
PD that could be reached in China by February 15, 2018. 
In comparison, a newly published article on the Pompe 
registry in China mentioned that it has only 78 registered 
patients [18]. Thus, our sample was, in fact, a complete 
set of all possible observations on Chinese patients with 
PDat the time of the survey.
Among the 78 surveyed patients with LOPD, 68 were 
adults and 10 were children. Since the scales we used to 
examine QOL and social support were personal meas-
ures, only adult patients could answer these questions 
by themselves. Hence, to maximize the reliability and 
accuracy of the answers, this study only included 68 adult 
patients.
Measurements
Dependent variable: quality of life
Quality of life was measured by the World Health Organ-
ization Quality of Life: Brief Version (WHOQOL-BREF), 
which was developed collaboratively by experts around 
the world and has been widely field-tested [19]. In an 
international survey of 11,830 adults from 23 countries, 
the WHOQOL group reported that WHOQOL-BREF 
was a reliable and cross-culturally valid assessment of 
QOL across all four domains [20]. According to the same 
research, the Cronbach’s alpha for the four domains in a 
Chinese sample was acceptable for the physical domain 
(0.82), the psychological domain (0.89), the social domain 
(0.76), and the environment domain (0.70). In addi-
tion, WHOQOL-BREF was extensively used in China to 
measure the QOL of older adults [21], patients with spe-
cific diseases [22–25], and patients with RDs [26]. The 
WHOQOL-BREF assesses individuals’ perceptions in 
the context of their culture and value systems and their 
personal goals, standards, and concerns. The instrument 
comprises 26 items that measure the following broad 
domains: physical, psychological, social relationships, 
and environment. The physical domain refers to the pain, 
energy, sleep, mobility, activities, medication, and work of 
a patient. The psychological domain emphasizes patients’ 
positive/negative feelings, cognitions, self-esteem, body 
image, and spirituality. The social domain evaluates per-
sonal relationships, and social and sex activities. The 
environmental domain focuses on patients’ subjective 
perceptions of safety, home environment, leisure, trans-
portation, and health/social facilities [19, 20]. A guideline 
published by the WHO illustrated in detail the scores cal-
culated for each domain [19]. The calculated maximum 
score is 100 in all domains, and scores are scaled in a pos-
itive direction (i.e., higher scores denote higher levels of 
quality of life). It has been noted that the cut-off for the 
WHOQOL-BREF varies among different groups of peo-
ple. Elderly studies found a critical value of 60 as the best 
cut-off point [27]. Yet another study on urban residents 
in China revealed that the two cut-off standards for low 
QOL, “70% of the maximum score” and “1 SD below the 
mean”, produced very different results for the probable 
prevalence of low QOL in the population under investi-
gation [28].
Independent variables
The independent variables in this study included soci-
odemographic variables (age, gender, education, employ-
ment status, and residence), medication history, disease 
economic burden, reliance on assistive devices, and social 
support.
Medication history was assessed by asking the 
respondents whether they received ERT with recombi-
nant human GAA (rhGAA, Myozyme) during the past 
12 months. Economic burden was measured in terms of 
catastrophic health expenditure (CHE). When the cost 
of treatment for a disease exceeds a certain percentage 
of income, the disease is considered to cause CHE for 
the patient. There is no commonly accepted criterion for 
defining CHE [29], and it varies from 10% of income [30, 
31], or 10% of household consumption [32] to 40% of dis-
posable income [33, 34]. In this study, we regarded out-
of-pocket health expenditures in excess of 10% of annual 
family income as an indicator of CHE. Reliance on assis-
tive devices is an important indicator of disability sta-
tus, and was measured with patients’ self-reports on the 
degree to which they needed to rely on assistive devices 
in their daily lives. Social support was measured with 
the Chinese Mandarin version of the Medical Outcomes 
Study Social Support Survey (MOS-SSS-CM), which is 
a brief, multidimensional, self-administered instrument 
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developed for patients with chronic conditions and has 
been validated previously among patients in mainland 
China [35]. The MOS-SSS-CM consists of 20 questions. 
One single item measured the structural support by 
asking “How many close friends and relatives (refers to 
people who you can get along with and talk about your 
concerns) do you have?”. The other 19 items measured 
functional support from four subscales (emotional/infor-
mational support, tangible support, affectionate support, 
and positive social interaction) [36].
Data analysis
In this study, the QOL was analyzed as sub-dimensional 
scores rather than a total score in order to reveal more 
specific information. Descriptive analyses included 
means and standard deviations of the continuous vari-
ables and percentages of categorical data. Univariate 
analysis of QOL included a t-test for binary variables, 
ANOVA test for categorical variables with more than two 
categories, and the Pearson correlation test for continu-
ous variables.
To help understand that a certain contributing factor 
in excess could reduce the QOL and vice versa, we con-
ducted a multivariable linear regression. Variables with 
p < 0.1 in the univariate analysis were included in the 
linear regression for multivariable analysis. All statisti-
cal analyses were conducted using R software (version 
3.5.0), including packages of dplyr (version 0.8.0.1) and 




Table  1 summarizes the main variables investigated in 
this study. A total of 68 adult patients with LOPD were 
included in the study. To better outline the patients’ 
social, medical, and economic characteristics, we com-
pared them with those of patients with other RDs who 
participated in the same cross-sectional survey.
The average age of adult patients with LOPD was 
30  years. The male-to-female ratio was around 1:1.1. 
About two-fifths of the participants lived in rural areas. 
More than 92% of them completed the nine-year manda-
tory education (or reached the level of middle school), 
while more than 70% completed 12  years of education 
(or reached the level of high school or above). Approxi-
mately one in five adult patients with LOPD is currently 
employed. Only 10% of the 68 patients used Myozyme in 
the past 12  months, and their average age was younger 
than that of non-users (27.9 years vs. 30.2 years). Never-
theless, nearly 70% of them suffered from CHE. Half of 
the adult patients with LOPD relied moderately on assis-
tive devices, and around 40% relied heavily on them.
Compared with the 1067 adult patients with RDs 
other than PD, the 68 patients with LOPD were younger 
(30.0  years among patients with LOPD vs. 35.7  years 
among patients with other RDs), experienced a shorter 
period between the onset of symptoms and first time 
to seek diagnosis (0.12 years vs. 2.75 years), yet a longer 
period between the first time to seek diagnosis and finally 
being diagnosed (4.25  years vs. 3.23  years). Patients 
with LOPD are also less likely to be employed (20.6% vs. 
52.7%) and more likely to rely on assistive devices (91.18% 
vs. 42.27%). The other factors, including gender, educa-
tion, and CHE, were similar between the two groups.
Conversely, the perceived social support of adult 
patients with LOPD in China appears to be similar to that 
of other Chinese patients with RDs. For patients with 
LOPD, the average scores of the four dimensions of social 
support were x = 72.87 (SD = 15.12) for tangible support, 
x = 55.70 (SD = 16.01) for emotional/informational sup-
port, x = 52.65 (SD = 15.85) for positive social interac-
tion, and x = 55.78 (SD = 17.35) for affectionate support. 
In terms of structural support, i.e., the average number of 
close friends and relatives that adult patients with LOPD 
feel at ease with and can talk to was 5.63. Patients with 
LOPD perceived that they received more tangible social 
support than other adult patients with RDs ( x = 72.9 vs. 
x = 64.8, p < 0.001). However, in the other three dimen-
sions, the amount of perceived social support or struc-
tural support did not seem to differ significantly between 
the patients with LOPD and those with other RDs.
In terms of QOL of adult patients with LOPD, the 
average scores for the four dimensions were: x = 33.77 
(SD = 18.28) for physical health, x = 43.81 (SD = 21.70) 
for psychological health, x = 39.43 (SD = 16.93) for envi-
ronmental health, and x = 46.20 (SD = 19.76) for social 
relationships. Compared with other adult patients with 
RDs, the physical health QOL of people with LOPD 
was significantly lower ( x = 33.8 vs. x = 48.2, p < 0.001), 
whereas their QOL in the other three dimensions did not 
differ significantly from those of other patients with RDs.
Univariate analysis
Table 2 presents the results of the univariate analysis of 
the four dimensions of QOL. At the level of p < 0.05, fac-
tors that significantly contributed to adult patients’ physi-
cal health QOL were age, reliance on assistive devices, 
and positive social interaction as an aspect of social sup-
port. As for psychological health QOL, the significant 
contributors were employment status, reliance on assis-
tive devices, and positive social interaction. As for envi-
ronmental health QOL, the significant contributors were 
age, employment status, reliance on assistive devices, 
and positive social interaction. As for social relation-
ship QOL, the significant contributors were employment 
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status, reliance on assistive devices, and positive social 
interaction.
Multivariable analysis
Results from the multiple linear regression are presented 
in Table 3.
With increased age, the patients experienced a signifi-
cant decrease in their physical health QOL (β = − 0.75, 
p < 0.01) and environmental health QOL (β = − 0.79, 
p < 0.01).
Educational level and CHE did not seem to corre-
late to different QOL scores in any dimension. Being 
employed is correlated with significantly higher scores 
in the domains of psychological health (β = 11.67, 
p < 0.05), environmental health (β = 11.29, p < 0.05), 
and social relationship QOL (β = 11.53, p < 0.05). Those 
who relied heavily on assistive devices had lower physi-
cal health (β = − 17.8, p < 0.05), lower psychological 
health (β = − 22.67, p < 0.05), lower environmental health 
(β = − 17.8, p < 0.05), and lower social relationship QOL 
(β = − 22.12, p < 0.01) than those who did not. Those 
who relied on assistive devices to some extent also had 
lower psychological health (β = − 16.12, p < 0.01) and 
lower social relationship QOL (β = − 15.89, p < 0.05) than 
those who did not. A one-unit increase in positive social 
interaction as a form of social support is correlated with a 
Table 1 Basic descriptive statistics
Bold values indicate statistical significance was defined as p < 0.05
† SD refers to the standard deviation











Age (years) 30.00 (7.39) 35.71 (11.21) < 0.001
 Age at the onset of symptoms 20.68 (6.71) 22.06 (15.60) 0.148
 Time between the onset of symptoms and first time to seek diagnosis 0.12 (4.73) 2.75 (6.28) < 0.001
 Time between the first time to seek diagnosis and being diagnosed 4.25 (5.03) 3.23 (6.25) < 0.001
Gender (= male%) 47.06 (32/68) 46.20 (493/1,067) 0.991
Education (%)
 Primary school or lower (6 years of edu) 7.35 (5/68) 12.00 (128/1,067) 0.505
 Middle school (9 years of edu) 22.06 (15/68) 21.84 (233/1,067)
 High school or above (12 years of edu) 70.59 (48/68) 66.17 (706/1,067)
Employment (= yes%) 20.59 (14/68) 52.67 (562/1,067) < 0.001
Catastrophic health expenditure (CHE) (= yes%) 67.21 (41/61) 70.03 (687/981) 0.748
Rural/Urban (= rural%) 35.29 (24/68) 24.55 (262/1,067) 0.067
Reliance on Assistive Devices (%)
 None 8.82 (6/68) 57.73 (616/1,067) < 0.001
 Some 50.00 (34/68) 27.09 (289/1,067)
 A lot 41.18 (28/68) 15.18 (162/1,067)
Medicated (= yes% “used ERT in the past 12 months”) 10.29 (7/68) – –
Social support (out of 100 points)
 Tangible support 72.87 (15.72) 64.78 (20.43) < 0.001
 Emotional/informational support 55.70 (16.01) 54.86 (18.21) 0.680
 Positive social interaction 52.65 (15.85) 53.72 (18.89) 0.594
 Affectionate support 55.78 (17.35) 56.48 (20.10) 0.751
 Structural support 5.63 (5.83) 5.62 (10.25) 0.990
Quality of life (out of 100 points)
 Physical health 33.77 (18.28) 48.22 (20.87) < 0.001
 Psychological health 43.81 (21.7) 43.25 (20.76) 0.837
 Environmental health 39.43 (16.93) 42.70 (17.80) 0.127
 Social relationships 46.20 (19.76) 48.56 (19.54) 0.342
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significant increase in physical health (β = 0.28, p < 0.05), 
psychological health (β = 0.71, p < 0.01), environmen-
tal health (β = 0.72, p < 0.01), and social relationships 
(β = 0.70, p < 0.01).
Discussion
To the best of our knowledge, this study is the first to 
comprehensively explore the levels and factors associ-
ated with QOL among patients with LOPD in China. 
Compared to previous research that compared patients 
with PD with the healthy population, our study makes 
a significant contribution in that we took patients with 
other RDs as the comparison group. We believe that 
our choice of comparison group better highlights the 
problems faced by adult patients with LOPD, which 
are otherwise neglected by the existing health care 
and support systems in China. Another contribution 
of our study is that we focused on sub-dimensional 
scores rather than the total score of QOL, which can 
provide more specific suggestions for RD healthcare 
policymaking.
We found that adult patients with LOPD and with 
other RDs in China had similar QOL in the domains 
of psychological and environmental health and social 
relationships; however, the former suffered an even 
lower QOL in the domain of physical health than the 
Table 2 Univariate analysis of the four dimensions of QOL
Bold values indicate statistical significance was defined as p < 0.05
† For categorical variables, statistics on QOL are presented as mean (SD). For continuous variables, statistics on QOL were presented as correlation coefficients
‡ For categorical variables, p values of the t-test or ANOVA results are shown. For continuous variables, the p values of the correlation test results are shown
Physical health Psychological health Environmental health Social relationships
Value† p  value‡ Value p valve Value p value Value p value
Age − 0.35 0.003 − 0.07 0.595 − 0.24 0.047 − 0.02 0.874
Gender
 Female 32.04(18.71) 0.411 42.94(20.7) 0.730 37.67(15.92) 0.372 47.22(19.72) 0.655
 Male 35.71(17.87) 44.79(23.07) 41.41(18.05) 45.05(20.06)
Education
 Primary school or lower 26.43(9.65) 0.467 22.5(20.33) 0.037 25(12.69) 0.125 36.67(22.52) 0.267
 Middle school 30.95(19.78) 40(26.25) 38.75(14.55) 41.67(16.37)
 High school or above 35.42(18.46) 47.22(19.13) 41.15(17.5) 48.61(20.29)
Employment
 No 30.03(17.57)  < 0.001 41.44(22.87) 0.020 37.27(17.82) 0.004 42.44(19.31) 0.001
 Yes 48.21(13.42) 52.98(13.42) 47.77(9.37) 60.71(14.41)
CHE
 No 37.32(18.74) 0.102 47.92(18.01) 0.340 42.5(15.75) 0.160 51.67(18.06) 0.142
 Yes 29.62(16.14) 42.38(22.46) 36.43(15.56) 43.7(20.31)
Rural/urban
 Urban 32.55(17.5) 0.477 44.7(18.9) 0.683 38.49(15.57) 0.568 44.7(20.26) 0.391
 Rural 36.01(19.81) 42.19(26.45) 41.15(19.41) 48.96(18.93)
Reliance on assistive devices
 None 54.76(18.16)  < 0.001 48.61(25.91) 0.022 55.73(25.88) 0.006 61.11(13.61) 0.004
 Some 36.66(16.83) 50(18.89) 41.54(14.18) 50.74(18.73)
 A lot 25.77(15.71) 35.27(21.89) 33.37(15.45) 37.5(18.77)
Medicated
 No 33.72(18.05) 0.958 43.78(22.59) 0.963 39.6(17.21) 0.797 46.86(20.19) 0.347
 Yes 34.18(21.71) 44.05(12.47) 37.95(15.35) 40.48(15.54)
Social support
 Tangible support 0.00 0.971 0.22 0.068 0.18 0.137 0.15 0.230
 Emotional/informational support 0.19 0.119 0.49  < 0.001 0.25 0.038 0.51  < 0.001
 Positive social interaction 0.37 0.002 0.55  < 0.001 0.41 0.001 0.60  < 0.001
 Affectionate support 0.12 0.314 0.46  < 0.001 0.21 0.081 0.39 0.001
 Structural support 0.09 0.459 0.35 0.004 0.20 0.109 0.36 0.003
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latter. This is, to some extent, consistent with previous 
findings in the literature where patients with PD were 
compared with the general population [8, 37, 38]. This 
is due to the fact that the special pathological features 
of PD, which cause the accumulation of glycogen in the 
skeletal muscles, heart, liver, and nervous system, may 
substantially restrict the ability of patients with LOPD 
to move or breathe [37]. Our study notes that physical 
vulnerability may influence patients with LOPD more 
than patients with other RDs. This finding calls for 
more efforts to promote physical-health-related QOL 
among people with LOPD.
According to a recent review, PD has now been con-
sidered as a multisystem disorder [39]. While IOPD is 
characterized by cardiomyopathy, respiratory insuffi-
ciency and severe muscle hypotonia, LOPD may gradu-
ally progress to significant motor disability, respiratory 
insufficiency, and neuropsychological dysfunction [39, 
40]. As the only standard of care that is available for 
patients with PD, ERT has proven to improve walking 
abilities [41] and respiratory function [42], and to reduce 
morbidity in adults with LOPD on long-term [43] or with 
early treatment [44]. For patients with IOPD, a recent 
study shows that ERT in combination with prophylactic 
immune tolerance induction initiated within the first 
month of life has yielded significant clinical benefits and 
survival rate in patients with CRIM-negative infantile PD, 
the most severe PD phenotype [45]. Hence, ERT can pos-
itively affect patients’ physical quality of life [11].
Meanwhile, as the study reveals, positive social inter-
action plays a very important role in increasing patients’ 
QOL across all domains. Positive social interaction was 
measured by three questions in the MOS-SSS instru-
ment: How often is each of the following kinds of sup-
port available to you if you need it? (1) someone to have 
a good time with; (2) someone to get together with for 
relaxation; and (3) someone to do something enjoyable 
with. Hence, in general, positive social interaction in this 
study refers to the possibility and frequency for patients 
with LOPD to engage in social interactions for fun and 
relaxation [46]. Due to the deteriorating physical con-
ditions suffered by patients, especially those without 
proper treatment, it is highly like that many patients with 
LOPD will gradually become disconnected with social 
life and lose positive social interaction with the world 
outside. Our study highlights the important role of posi-
tive social interaction in enhancing patients QOL, which 
can only be achieved by involving not only the patients 
Table 3 Linear regression results of the four dimensions of QOL
Bold values indicate statistical significance was defined as p < 0.05
***p < 0.001; **p < 0.01; *p < 0.05
Physical health Psychological health Environmental health Social relationships
Age − 0.75 [− 1.25, − 0.24]** – − 0.79 [− 1.27, − 0.3]** –
Education
 Primary school or lower – Reference – –
 Middle school – − 4.07 [− 20.68, 12.53] – –
 High school or above – − 4.3 [− 19.71, 11.11] – –
Employment
 No Reference Reference Reference Reference
 Yes 7.98 [− 1.83, 17.8] 11.67 [1.47, 21.87]* 11.29 [2.4, 20.19]* 11.53 [1.96, 21.11]*
CHE
 No Reference – – –
 Yes − 6.48 [− 14.68, 1.73] – – –
Reliance on assistive devices
 None Reference Reference Reference Reference
 Some − 10.58 [− 26.43, 5.28] − 16.12 [− 30.7, − 1.55]* − 12.08 [− 25.05, 0.88] − 15.89 [− 29.62, − 2.17]*
 A lot − 17.8 [− 34.24, − 1.37]* − 22.67 [− 37.67, − 7.66]** − 17.8 [− 31.21, − 4.4]* − 22.12 [− 36.26, − 7.98]**
Social support
 Tangible support – − 0.01 [− 0.31, 0.3] – –
 Emotional/informational sup‑
port
– − 0.25 [− 0.8, 0.3] − 0.29 [− 0.74, 0.16] − 0.25 [− 0.73, 0.23]
 Positive social interaction 0.28 [0.04, 0.51]* 0.71 [0.21, 1.21]** 0.72 [0.29, 1.15]** 0.7 [0.24, 1.16]**
 Affectionate support – − 0.21 [− 0.54, 0.13] − 0.22 [− 0.52, 0.07] − 0.2 [− 0.52, 0.12]
 Structural support – − 0.15 [− 0.86, 0.57] 0.16 [− 0.51, 0.82] − 0.16 [− 0.85, 0.53]
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and their families but also the community and the pub-
lic. On the one hand, direct support provided by social 
workers or local non-government organizations to help 
patients and families address difficulties in daily living 
will greatly alleviate the caring burden and thus allow 
the main caregivers to allocate time and energy for the 
patients to have quality social life. On the other hand, 
elevating the awareness of the public on RDs in general 
and on PD in particular will eliminate misunderstandings 
and discriminations against patients with RDs, which will 
in turn remove the psychological barriers and stress that 
patients may have that prevent them from actively engag-
ing with others [47]. By knowing the patients better, the 
public will also be mobilized to initiate more positive 
interactions with the patient community, hence. creating 
a more supportive social environment for patients with 
LOPD and other RDs.
No statistical differences were observed in the domains 
of psychological health, environmental health, and social 
relationships of QOL. Such findings are consistent with a 
previous study in Italian which found that patients with 
different RDs shared the same feeling of hopelessness 
and a sense of being marginalized that would strongly 
and negatively affect their self-image and life orientation 
[47]. The impact of RDs on psychological, environmen-
tal, and social QOL may be more closely related to social 
misconceptions and even stigma of RDs and patients 
with RDs than to the physiological nature of the diseases 
themselves [47]. Data from the Australian adolescent 
patients with RDs revealed that nearly half (46.4%) of 
the patients had ever experienced bullying victimization 
in school, and that many of their classmates (75.6%) and 
the teachers (53.7%) did not understand the child’s rare 
health condition [48]. Another study on patients with 
Alpha-1 antitrypsin deficiency (AATD) in the United 
States reported that the most memorable stigmatization 
experiences of the participants were rejection from fam-
ily members, friends and romantic partners, followed by 
contempt from employers and health care providers [47]. 
Regardless of the type of patients with RDs, their percep-
tions of psychological stress, a sense of security from the 
environment, and social interactions with others could 
be similar. Recent research has emphasized that psycho-
logical adjustments are beneficial to patients’ well-being 
[49]. Yet more studies are needed to identify practical 
and effective ways for patients with LOPD and other RDs 
to improve their mental health.
ERT has reduced morbidity, but QOL is still impacted. 
Therefore it is important to identify ways to improve 
their QOL should be a core mission of patient-centered 
care. This study sought to contribute to this mission by 
exploring the contributors of patients’ QOL. Among all 
the potential contributors that we included in this study, 
gender did not seem to make a difference in terms of the 
four domains of QOL among the patients with LOPD in 
China. Age was negatively associated with the physical 
and environmental health domains of QOL, but it had 
no significant association with mental health or social 
relationships.
A systematic review among 1,214 patients with RDs 
in the United States noted that income level is positively 
associated with QOL in all domains [50]. Our study 
partly echoes these findings. On the one hand, we found 
that employment is significantly correlated with patients’ 
psychological, environmental, and social relationship 
QOL. This is reasonable because employed patients 
tend to perform better in their social roles and have 
more chances to interact with other people. Meanwhile, 
higher levels of QOL may also allow patients to have a 
higher employment rate. On the other hand, the associa-
tion between employment and physical health were sig-
nificant in univariate analysis but became non-significant 
in the multivariable model, implying a weak association 
between employment and patients’ physical health. It 
may imply that the association between employment and 
physical conditions might be mediated or moderated by 
other factors, such as positive social interaction. It is also 
possible that having a job may increase the patients’ sub-
jective feelings of physical health. Therefore, policymak-
ers and caregivers may need to think about how to create 
work opportunities that are suitable for these patients.
One surprising finding of our study is that there was 
no statistical difference between patients with LOPD 
and those with other RDs in terms of the proportion of 
patients suffering from CHE, even though ERT is recog-
nized as one of the most expensive orphan drugs in the 
world. We think the most likely reason lies in the indica-
tor of CHE itself. CHE is a binary indicator used for all 
populations and does not take into consideration disease-
specific characteristics. Studies have indicated that RDs 
tend to pose a high economic burden on patients [51, 
52]; in other words, the existing benchmark for judging 
CHE may be able to distinguish between rare and com-
mon diseases, but lacks sufficient sensitivity to distin-
guish between patients with PD and with other RDs. This 
inadequate sensitivity may also explain why nearly 70% of 
patients with RDs, which is much higher than the aver-
age proportion of CHE among the general population 
(12.9%) [53].
The problem faced by patients with PD, i.e., high 
healthcare expenditures, does not exist in China alone—
in Europe, the average cost of ERT for PD is approxi-
mately EUR 300,000 (approximately RMB 2,360,000) per 
patient per year [1]. The financial burden of patients with 
PD in China can be even more devastating, because, at 
the time of the survey, almost all patients with PD must 
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pay out-of-pocket. There is almost no insurance coverage 
from the government or the market to help alleviate the 
burden.
Another noteworthy finding of our study was that there 
is no significant association between CHE and the QOL 
in patients with LOPD, which is inconsistent with stud-
ies conducted in the United States and Europe [54, 55]. 
Although patients can have adverse infusion reactions, a 
systematic review of 21 international articles concluded 
that most adverse events were mild or moderate, and ERT 
is well tolerated in general [56]. Besides, reduced bodily 
pain, improved motor performance and ambulation sta-
tus, and promoted patients’ quality of life in both physical 
and mental components was widely observed especially 
at the early stages of treatment. Hence, despite its high 
cost, ERT has been highlighted in some countries as a 
significant promoter of QOL [57]. Given the high price 
of ERT and the nearly complete lack of health insurance 
coverage on it in China at the time of this survey, a higher 
CHE may indicate the utilization of ERT or other forms 
of treatment, which should have potentially helped, at 
least, increase the patients’ physical health. However, this 
is not what we found in our study. Although no existing 
literature could provide explanation to such a finding, 
based our knowledge on the community of patients with 
LOPD in China, the majority of the patients who received 
ERT used the medicine neither continuously nor with 
sufficient doses. As a result, the effectiveness of the treat-
ment was quite limited.
This study found that a higher level of reliance on 
assistive devices was negatively associated with all four 
dimensions of QOL. A large-scale study using the Inter-
national Pompe Survey also revealed that wheelchair- 
and ventilator-dependent patients were more likely to 
report lower health-related QOL in terms of physical 
functioning, physical role functioning, and social func-
tioning than the general population [8]. Yet in the same 
study, functional disability was not found to be related to 
mental health-related QOL. However, our study found 
otherwise; that is, the influence of functional disability 
was pervasive on QOL in patients with LOPD. This may 
be because patients who rely heavily on assistive devices 
are less likely to go outdoors and have fewer chances to 
interact with others. More attention should be paid to 
these socially isolated patients. Future research should 
explore the impact of an active lifestyle, especially among 
patients who require assistive devices. The findings 
should be tested to determine whether they can be gener-
alized to the global context.
Previous studies on QOL in patients with LOPD 
mostly focused on the financial and physical burdens 
presented by the disease; however, the humanistic aspect 
was largely overlooked. Dekker et  al. indicated that the 
painful processes of learning, coping, and adapting to 
disease-related psychology could induce a humanistic 
burden on the social capital and social support of the 
patients and their caregivers [10]. Our findings indi-
cated that promoting positive, successful interactions 
should be emphasized in improving QOL in patients with 
LOPD beyond the conventional emphasis on medication. 
Patient organizations may consider providing opportuni-
ties for patients to talk with their peers and share good 
news with friends in their programs. This study also 
found that unlike social interaction, tangible emotional/
informational and affectionate social support might not 
be associated with patients’ QOL. It is worthy of note 
that one review of the spiritual needs of chronic disease 
patients emphasized that the feeling of being in charge or 
being helpful was more effective in improving patients’ 
psychological resilience than the feeling of being weak 
or being helped [58]. Therefore, when promoting social 
interactions, QOL promotional programs and patient 
organizations may try to offer more opportunities for 
reciprocal interactions rather than treating the patients 
as recipients alone.
Limitations
There are a few limitations to this study. First, this is a 
self-response cross-sectional survey that involves a rather 
small sample size. The inference made from this sample 
needs to be carefully examined. Second, the data were 
collected by an online survey. Although this approach 
could maximize the coverage of patients residing spo-
radically over a large country, whether or not the subjects 
would be able to understand the questions correctly or to 
provide authentic answers are of concern. Third, we did 
not include other possible factors associated with LOPD 
or QOL, such as comorbidities, clinical symptoms, and 
accessibility to medical resources. Fourth, there is nei-
ther a specific QOL scale for patients with RDs nor for 
patients with LOPD in particular. Therefore, we used 
the WHOQOL-BREF, which consists of abstract ques-
tions that are not suitable for children. Hence, non-adult 
patients with LOPD or IOPD were excluded from our 
study. Further relevant studies are warranted.
Conclusion
This study comprehensively explored the levels of and 
contributors to the QOL of adult patients with LOPD in 
China. Measured by the WHOQOL-BREF, the average 
physical health QOL for this group of patients was very 
low. However, social interactions, especially those real-
ized via employment, were found to play an important 
role in QOL in patients with LOPD in almost all dimen-
sions. Compared with offering tangible, informational, or 
affectionate social support, it might be more important to 
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encourage patients with LOPD to be socially active and 
to help them better included in social life. Additionally, 
most Chinese patients with LOPD cannot afford ERT due 
to inadequate financial support. They inevitably become 
disabled at an earlier age, which will, in turn, constrain 
their social life and decrease their QOL. Hence, how to 
provide adult patients with LOPD equal or even more 
opportunities to be socially engaged is something that 
healthcare providers and policymakers need to consider.
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